CPSE:GMAB

Stock Analysis Report

Executive Summary

Genmab A/S, a biotechnology company, creates and develops antibody therapeutics for the treatment of cancer primarily in Denmark.


Snowflake Analysis

Flawless balance sheet with reasonable growth potential.


Similar Companies

Share Price & News

How has Genmab's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: GMAB has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

6.6%

GMAB

7.1%

DK Biotechs

1.9%

DK Market


1 Year Return

26.5%

GMAB

26.9%

DK Biotechs

6.0%

DK Market

Return vs Industry: GMAB matched the Danish Biotechs industry which returned 25.6% over the past year.

Return vs Market: GMAB exceeded the Danish Market which returned 5.2% over the past year.


Shareholder returns

GMABIndustryMarket
7 Day6.6%7.1%1.9%
30 Day-4.5%-8.2%-4.3%
90 Day0.1%-1.2%-4.4%
1 Year26.5%26.5%27.8%26.9%8.2%6.0%
3 Year15.6%15.6%13.2%11.2%36.1%24.7%
5 Year181.1%181.1%36.6%32.1%30.3%13.8%

Price Volatility Vs. Market

How volatile is Genmab's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Genmab undervalued compared to its fair value and its price relative to the market?

19.4%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: GMAB (DKK1468.5) is trading below our estimate of fair value (DKK1820.88)

Significantly Below Fair Value: GMAB is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: GMAB is good value based on its PE Ratio (42.7x) compared to the Biotechs industry average (43.3x).

PE vs Market: GMAB is poor value based on its PE Ratio (42.7x) compared to the Danish market (12.8x).


Price to Earnings Growth Ratio

PEG Ratio: GMAB is poor value based on its PEG Ratio (1.7x)


Price to Book Ratio

PB vs Industry: GMAB is overvalued based on its PB Ratio (6.8x) compared to the DK Biotechs industry average (6.8x).


Next Steps

Future Growth

How is Genmab forecast to perform in the next 1 to 3 years based on estimates from 20 analysts?

25.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: GMAB's forecast earnings growth (25% per year) is above the savings rate (-0.3%).

Earnings vs Market: GMAB's earnings (25% per year) are forecast to grow faster than the Danish market (12.1% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: GMAB's revenue (19.8% per year) is forecast to grow faster than the Danish market (6% per year).

High Growth Revenue: GMAB's revenue (19.8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: GMAB's Return on Equity is forecast to be low in 3 years time (16.1%).


Next Steps

Past Performance

How has Genmab performed over the past 5 years?

26.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: GMAB has a high level of non-cash earnings.

Growing Profit Margin: GMAB's current net profit margins (40.4%) are lower than last year (48.7%).


Past Earnings Growth Analysis

Earnings Trend: GMAB's earnings have grown significantly by 26.3% per year over the past 5 years.

Accelerating Growth: GMAB's earnings growth over the past year (47.1%) exceeds its 5-year average (26.3% per year).

Earnings vs Industry: GMAB earnings growth over the past year (47.1%) exceeded the Biotechs industry 14.9%.


Return on Equity

High ROE: GMAB's Return on Equity (15.4%) is considered low.


Next Steps

Financial Health

How is Genmab's financial position?


Financial Position Analysis

Short Term Liabilities: GMAB's short term assets (DKK14.0B) exceed its short term liabilities (DKK938.0M).

Long Term Liabilities: GMAB's short term assets (DKK14.0B) exceed its long term liabilities (DKK158.0M).


Debt to Equity History and Analysis

Debt Level: GMAB is debt free.

Reducing Debt: GMAB had no debt 5 years ago.

Debt Coverage: GMAB has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: GMAB has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Genmab's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate GMAB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate GMAB's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if GMAB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if GMAB's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of GMAB's dividend in 3 years as they are not forecast to pay a notable one for the Danish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.1yrs

Average management tenure


CEO

Jan G. van de Winkel (58yo)

9.83s

Tenure

ø35,200,000

Compensation

Dr. Jan G. J. van de Winkel, Ph.D., serves as a Member of Advisory board at Thuja Capital Management B.V. Dr. van de Winkel served as a Member of Scientific Advisory Board. He is a Co-Founder of Genmab A/S ...


CEO Compensation Analysis

Compensation vs Market: Jan G.'s total compensation ($USD5.13M) is above average for companies of similar size in the Danish market ($USD3.18M).

Compensation vs Earnings: Jan G.'s compensation has increased by more than 20% in the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Jan G. van de Winkel
Co-Founder9.83yrsø35.20m1.03% DKK981.7m
Peter Kristensen
Associate Director of Legal & Non-Independent Director4.25yrsø800.00k0.00031% DKK296.9k
Judith Klimovsky
Executive VP & Chief Development Officer3.17yrsø17.00mno data
Mijke Zachariasse
Director of Protein Production & Chemistry and Non-Independent Director1.08yrsø300.00kno data
Daniel Bruno
VP, Corporate Controller & Non-Independent Director4.25yrsø800.00kno data
Anthony Pagano
Executive VP & CFO0.083yrno datano data
Anthony Mancini
Executive VP & COO0.083yrno datano data
Peter Ros
Senior Director of Finance & Accountingno datano datano data
Marisol Peron
Head and Corporate VP of Communications & Investor Relations1.08yrsno datano data
Birgitte Stephensen
Senior Vice President of IPR & Legal10.25yrsno datano data

2.1yrs

Average Tenure

45yo

Average Age

Experienced Management: GMAB's management team is considered experienced (2.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Peter Kristensen
Associate Director of Legal & Non-Independent Director4.25yrsø800.00k0.00031% DKK296.9k
Mijke Zachariasse
Director of Protein Production & Chemistry and Non-Independent Director1.08yrsø300.00kno data
Daniel Bruno
VP, Corporate Controller & Non-Independent Director4.25yrsø800.00kno data
Anders Pedersen
Non-Independent Director16.42yrsø1.40m0.013% DKK12.8m
Deirdre Connelly
Independent Chairman of the Board0.083yrø2.20m0.0034% DKK3.2m
Rolf Hoffmann
Independent Director3.08yrsø1.50m0.0016% DKK1.5m
Pernille Erenbjerg
Independent Deputy Chairman0.083yrø1.10m0.0049% DKK4.7m
Jonathan Peacock
Independent Director0.083yrno datano data
Paolo Paoletti
Independent Director5.25yrsø1.10m0.0051% DKK4.9m

3.1yrs

Average Tenure

58yo

Average Age

Experienced Board: GMAB's board of directors are considered experienced (3.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.8%.


Top Shareholders

Company Information

Genmab A/S's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Genmab A/S
  • Ticker: GMAB
  • Exchange: CPSE
  • Founded: 1999
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ø95.762b
  • Shares outstanding: 65.21m
  • Website: https://www.genmab.com

Number of Employees


Location

  • Genmab A/S
  • Kalvebod Brygge 43
  • Copenhagen
  • Capital Region of Denmark
  • 1560
  • Denmark

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
GNMS.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDOct 2000
GMABCPSE (OMX Nordic Exchange Copenhagen)YesOrdinary SharesDKDKKOct 2000
GE9DB (Deutsche Boerse AG)YesOrdinary SharesDEEUROct 2000
0MGBLSE (London Stock Exchange)YesOrdinary SharesGBDKKOct 2000
GMABNasdaqGS (Nasdaq Global Select)SPONSORED ADSUSUSDMay 2013
GE91BST (Boerse-Stuttgart)SPONSORED ADSDEEURMay 2013

Biography

Genmab A/S, a biotechnology company, creates and develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM) indications; and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL) indications. Its products under development include Ofatumumab to treat multiple sclerosis; Tisotumab vedotin for treating cervical and ovarian cancers, and solid tumors; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company’s products under development also comprise Teprotumumab for the treatment of thyroid eye disease; Camidanlumab tesirine (ADCT-301) to treat Hodgkin lymphoma and solid tumors; HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat acute myeloid leukemia (AML); JNJ-64007957 and JNJ-64407564 for MM; JNJ-63898081 to treat solid tumors; JNJ-67571244 to treat AML or myelodysplastic syndrome; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked antibodies, bispecific antibodies, and immune effector function enhanced antibodies. The company has a commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and a strategic collaboration agreement with Tempus to advance various disease targets and biomarkers. It also has a research collaboration and license agreement with Immatics Biotechnologies GmbH to discover and develop next-generation bispecific immunotherapies for treating multiple cancer indications; and CureVac AG for the research and development of differentiated mRNA-based antibody products. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/07 20:55
End of Day Share Price2020/04/07 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.